A citation-based method for searching scientific literature

Carina Heydt, Jan Rehker, Roberto Pappesch, Theresa Buhl, Markus Ball, Udo Siebolts, Anja Haak, Philipp Lohneis, Reinhard Büttner, Axel M Hillmer, Sabine Merkelbach-Bruse. Sci Rep 2020
Times Cited: 12







List of co-cited articles
48 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Implementing TMB measurement in clinical practice: considerations on assay requirements.
Reinhard Büttner, John W Longshore, Fernando López-Ríos, Sabine Merkelbach-Bruse, Nicola Normanno, Etienne Rouleau, Frédérique Penault-Llorca. ESMO Open 2019
100
50

Tumor mutational load predicts survival after immunotherapy across multiple cancer types.
Robert M Samstein, Chung-Han Lee, Alexander N Shoushtari, Matthew D Hellmann, Ronglai Shen, Yelena Y Janjigian, David A Barron, Ahmet Zehir, Emmet J Jordan, Antonio Omuro,[...]. Nat Genet 2019
898
41

Optimizing panel-based tumor mutational burden (TMB) measurement.
J Budczies, M Allgäuer, K Litchfield, E Rempel, P Christopoulos, D Kazdal, V Endris, M Thomas, S Fröhling, S Peters,[...]. Ann Oncol 2019
50
41

First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.
David P Carbone, Martin Reck, Luis Paz-Ares, Benjamin Creelan, Leora Horn, Martin Steins, Enriqueta Felip, Michel M van den Heuvel, Tudor-Eliade Ciuleanu, Firas Badin,[...]. N Engl J Med 2017
33

Tumor Mutational Burden and Response Rate to PD-1 Inhibition.
Mark Yarchoan, Alexander Hopkins, Elizabeth M Jaffee. N Engl J Med 2017
973
33

Methods of measurement for tumor mutational burden in tumor tissue.
Bárbara Meléndez, Claude Van Campenhout, Sandrine Rorive, Myriam Remmelink, Isabelle Salmon, Nicky D'Haene. Transl Lung Cancer Res 2018
75
33

Signatures of mutational processes in human cancer.
Ludmil B Alexandrov, Serena Nik-Zainal, David C Wedge, Samuel A J R Aparicio, Sam Behjati, Andrew V Biankin, Graham R Bignell, Niccolò Bolli, Ake Borg, Anne-Lise Børresen-Dale,[...]. Nature 2013
33

Genetic basis for clinical response to CTLA-4 blockade in melanoma.
Alexandra Snyder, Vladimir Makarov, Taha Merghoub, Jianda Yuan, Jesse M Zaretsky, Alexis Desrichard, Logan A Walsh, Michael A Postow, Phillip Wong, Teresa S Ho,[...]. N Engl J Med 2014
33

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic.
T A Chan, M Yarchoan, E Jaffee, C Swanton, S A Quezada, A Stenzinger, S Peters. Ann Oncol 2019
451
33

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.
Zachary R Chalmers, Caitlin F Connelly, David Fabrizio, Laurie Gay, Siraj M Ali, Riley Ennis, Alexa Schrock, Brittany Campbell, Adam Shlien, Juliann Chmielecki,[...]. Genome Med 2017
33

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.
Matthew D Hellmann, Tudor-Eliade Ciuleanu, Adam Pluzanski, Jong Seok Lee, Gregory A Otterson, Clarisse Audigier-Valette, Elisa Minenza, Helena Linardou, Sjaak Burgers, Pamela Salman,[...]. N Engl J Med 2018
33

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
Naiyer A Rizvi, Matthew D Hellmann, Alexandra Snyder, Pia Kvistborg, Vladimir Makarov, Jonathan J Havel, William Lee, Jianda Yuan, Phillip Wong, Teresa S Ho,[...]. Science 2015
33

Size matters: Dissecting key parameters for panel-based tumor mutational burden analysis.
Ivo Buchhalter, Eugen Rempel, Volker Endris, Michael Allgäuer, Olaf Neumann, Anna-Lena Volckmar, Martina Kirchner, Jonas Leichsenring, Amelie Lier, Moritz von Winterfeld,[...]. Int J Cancer 2019
65
25

Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations of the Quality in Pathology Study.
Albrecht Stenzinger, Volker Endris, Jan Budczies, Sabine Merkelbach-Bruse, Daniel Kazdal, Wolfgang Dietmaier, Nicole Pfarr, Udo Siebolts, Michael Hummel, Sylvia Herold,[...]. J Thorac Oncol 2020
38
25

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.
Aaron M Goodman, Shumei Kato, Lyudmila Bazhenova, Sandip P Patel, Garrett M Frampton, Vincent Miller, Philip J Stephens, Gregory A Daniels, Razelle Kurzrock. Mol Cancer Ther 2017
876
25

CANCER IMMUNOLOGY. The "cancer immunogram".
Christian U Blank, John B Haanen, Antoni Ribas, Ton N Schumacher. Science 2016
388
25

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.
Matthew D Hellmann, Margaret K Callahan, Mark M Awad, Emiliano Calvo, Paolo A Ascierto, Akin Atmaca, Naiyer A Rizvi, Fred R Hirsch, Giovanni Selvaggi, Joseph D Szustakowski,[...]. Cancer Cell 2018
377
25

Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts.
Jean-David Fumet, Caroline Truntzer, Mark Yarchoan, Francois Ghiringhelli. Eur J Cancer 2020
29
25

Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project.
Diana M Merino, Lisa M McShane, David Fabrizio, Vincent Funari, Shu-Jen Chen, James R White, Paul Wenz, Jonathan Baden, J Carl Barrett, Ruchi Chaudhary,[...]. J Immunother Cancer 2020
58
25

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
Dung T Le, Jennifer N Uram, Hao Wang, Bjarne R Bartlett, Holly Kemberling, Aleksandra D Eyring, Andrew D Skora, Brandon S Luber, Nilofer S Azad, Dan Laheru,[...]. N Engl J Med 2015
25

Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.
Hira Rizvi, Francisco Sanchez-Vega, Konnor La, Walid Chatila, Philip Jonsson, Darragh Halpenny, Andrew Plodkowski, Niamh Long, Jennifer L Sauter, Natasha Rekhtman,[...]. J Clin Oncol 2018
573
25

Tumor mutational burden quantification from targeted gene panels: major advancements and challenges.
Laura Fancello, Sara Gandini, Pier Giuseppe Pelicci, Luca Mazzarella. J Immunother Cancer 2019
81
25

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.
Ferdinandos Skoulidis, Michael E Goldberg, Danielle M Greenawalt, Matthew D Hellmann, Mark M Awad, Justin F Gainor, Alexa B Schrock, Ryan J Hartmaier, Sally E Trabucco, Laurie Gay,[...]. Cancer Discov 2018
475
16

Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis.
Steve Lu, Julie E Stein, David L Rimm, Daphne W Wang, J Michael Bell, Douglas B Johnson, Jeffrey A Sosman, Kurt A Schalper, Robert A Anders, Hao Wang,[...]. JAMA Oncol 2019
140
16

Alternative Splicing in Tumors - A Path to Immunogenicity?
Jill E Slansky, Paul T Spellman. N Engl J Med 2019
18
16

Cancer stemness, intratumoral heterogeneity, and immune response across cancers.
Alex Miranda, Phineas T Hamilton, Allen W Zhang, Swetansu Pattnaik, Etienne Becht, Artur Mezheyeuski, Jarle Bruun, Patrick Micke, Aurélien de Reynies, Brad H Nelson. Proc Natl Acad Sci U S A 2019
81
16

Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.
Naiyer A Rizvi, Byoung Chul Cho, Niels Reinmuth, Ki Hyeong Lee, Alexander Luft, Myung-Ju Ahn, Michel M van den Heuvel, Manuel Cobo, David Vicente, Alexey Smolin,[...]. JAMA Oncol 2020
95
16

Immune resistance orchestrated by the tumor microenvironment.
Thomas F Gajewski, Yuru Meng, Christian Blank, Ian Brown, Aalok Kacha, Justin Kline, Helena Harlin. Immunol Rev 2006
309
16

UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma.
Yochai Wolf, Osnat Bartok, Sushant Patkar, Gitit Bar Eli, Sapir Cohen, Kevin Litchfield, Ronen Levy, Alejandro Jiménez-Sánchez, Sophie Trabish, Joo Sang Lee,[...]. Cell 2019
95
16

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
Aurélien Marabelle, Marwan Fakih, Juanita Lopez, Manisha Shah, Ronnie Shapira-Frommer, Kazuhiko Nakagawa, Hyun Cheol Chung, Hedy L Kindler, Jose A Lopez-Martin, Wilson H Miller,[...]. Lancet Oncol 2020
173
16

The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine.
Andrea Garofalo, Lynette Sholl, Brendan Reardon, Amaro Taylor-Weiner, Ali Amin-Mansour, Diana Miao, David Liu, Nelly Oliver, Laura MacConaill, Matthew Ducar,[...]. Genome Med 2016
99
16

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
Dung T Le, Jennifer N Durham, Kellie N Smith, Hao Wang, Bjarne R Bartlett, Laveet K Aulakh, Steve Lu, Holly Kemberling, Cara Wilt, Brandon S Luber,[...]. Science 2017
16

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.
Fred R Hirsch, Abigail McElhinny, Dave Stanforth, James Ranger-Moore, Malinka Jansson, Karina Kulangara, William Richardson, Penny Towne, Debra Hanks, Bharathi Vennapusa,[...]. J Thorac Oncol 2017
720
16

Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer.
Siddhartha Devarakonda, Federico Rotolo, Ming-Sound Tsao, Irena Lanc, Elisabeth Brambilla, Ashiq Masood, Ken A Olaussen, Robert Fulton, Shingo Sakashita, Anne McLeer-Florin,[...]. J Clin Oncol 2018
93
16

PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project.
Ming Sound Tsao, Keith M Kerr, Mark Kockx, Mary-Beth Beasley, Alain C Borczuk, Johan Botling, Lukas Bubendorf, Lucian Chirieac, Gang Chen, Teh-Ying Chou,[...]. J Thorac Oncol 2018
310
16

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.
Bertrand Routy, Emmanuelle Le Chatelier, Lisa Derosa, Connie P M Duong, Maryam Tidjani Alou, Romain Daillère, Aurélie Fluckiger, Meriem Messaoudene, Conrad Rauber, Maria P Roberti,[...]. Science 2018
16

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.
Eliezer M Van Allen, Diana Miao, Bastian Schilling, Sachet A Shukla, Christian Blank, Lisa Zimmer, Antje Sucker, Uwe Hillen, Marnix H Geukes Foppen, Simone M Goldinger,[...]. Science 2015
16

Neoantigens in cancer immunotherapy.
Ton N Schumacher, Robert D Schreiber. Science 2015
16

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy.
Razvan Cristescu, Robin Mogg, Mark Ayers, Andrew Albright, Erin Murphy, Jennifer Yearley, Xinwei Sher, Xiao Qiao Liu, Hongchao Lu, Michael Nebozhyn,[...]. Science 2018
601
16

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Hossein Borghaei, Luis Paz-Ares, Leora Horn, David R Spigel, Martin Steins, Neal E Ready, Laura Q Chow, Everett E Vokes, Enriqueta Felip, Esther Holgado,[...]. N Engl J Med 2015
16

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
Julie Brahmer, Karen L Reckamp, Paul Baas, Lucio Crinò, Wilfried E E Eberhardt, Elena Poddubskaya, Scott Antonia, Adam Pluzanski, Everett E Vokes, Esther Holgado,[...]. N Engl J Med 2015
16

Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.
Matthew D Hellmann, Tavi Nathanson, Hira Rizvi, Benjamin C Creelan, Francisco Sanchez-Vega, Arun Ahuja, Ai Ni, Jacki B Novik, Levi M B Mangarin, Mohsen Abu-Akeel,[...]. Cancer Cell 2018
409
16

Assessment of Capture and Amplicon-Based Approaches for the Development of a Targeted Next-Generation Sequencing Pipeline to Personalize Lymphoma Management.
Stacy S Hung, Barbara Meissner, Elizabeth A Chavez, Susana Ben-Neriah, Daisuke Ennishi, Martin R Jones, Hennady P Shulha, Fong Chun Chan, Merrill Boyle, Robert Kridel,[...]. J Mol Diagn 2018
32
16

Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists.
Lawrence J Jennings, Maria E Arcila, Christopher Corless, Suzanne Kamel-Reid, Ira M Lubin, John Pfeifer, Robyn L Temple-Smolkin, Karl V Voelkerding, Marina N Nikiforova. J Mol Diagn 2017
233
16

Sequencing technologies - the next generation.
Michael L Metzker. Nat Rev Genet 2010
16

Evaluation of Hybridization Capture Versus Amplicon-Based Methods for Whole-Exome Sequencing.
Eric Samorodnitsky, Benjamin M Jewell, Raffi Hagopian, Jharna Miya, Michele R Wing, Ezra Lyon, Senthilkumar Damodaran, Darshna Bhatt, Julie W Reeser, Jharna Datta,[...]. Hum Mutat 2015
111
16

Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.
Donavan T Cheng, Talia N Mitchell, Ahmet Zehir, Ronak H Shah, Ryma Benayed, Aijazuddin Syed, Raghu Chandramohan, Zhen Yu Liu, Helen H Won, Sasinya N Scott,[...]. J Mol Diagn 2015
870
16

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe,[...]. N Engl J Med 2016
16

Bioinformatic Methods and Bridging of Assay Results for Reliable Tumor Mutational Burden Assessment in Non-Small-Cell Lung Cancer.
Han Chang, Ariella Sasson, Sujaya Srinivasan, Ryan Golhar, Danielle M Greenawalt, William J Geese, George Green, Kim Zerba, Stefan Kirov, Joseph Szustakowski. Mol Diagn Ther 2019
19
8

ecTMB: a robust method to estimate and classify tumor mutational burden.
Lijing Yao, Yao Fu, Marghoob Mohiyuddin, Hugo Y K Lam. Sci Rep 2020
5
20


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.